Form 4: Twist Bioscience COO Awarded Restricted Stock Units

Twist Bioscience's President and COO, Patrick John Finn, was granted 53,634 restricted stock units on December 4, 2024.

Summary

• Patrick John Finn, President and COO of Twist Bioscience, was awarded 53,634 restricted stock units (RSUs) on December 4, 2024.
• The RSUs vest over a 48-month period, with 1/16th of the total units vesting each quarter starting from November 20, 2024.
• The vesting is contingent upon Mr. Finn's continuous service with the company through each vesting date.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management interests with shareholders. There are no negative implications.

Positives

• The grant of RSUs aligns the executive's interests with the long-term performance of the company.
• The vesting schedule encourages continued service and commitment from the COO.

Risks

• The value of the RSUs is subject to the market price of Twist Bioscience stock, which can fluctuate.
• If Mr. Finn leaves the company before the vesting period is complete, he may forfeit unvested RSUs.

Future Outlook

The vesting of the RSUs is contingent on the continued service of the executive over the next 48 months.

Industry Context

Stock-based compensation is a common practice in the biotechnology industry to attract and retain key executives.

Comparison to Industry Standards

• The use of restricted stock units is a standard form of executive compensation in the biotech industry.
• Vesting schedules of 48 months are also common, aligning executive incentives with long-term company performance.
• Companies like Illumina and Agilent also use similar equity-based compensation plans for their executives.

Stakeholder Impact

• Shareholders may view the RSU grant positively as it incentivizes the COO to contribute to the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

restricted stock units, RSU, stock award, executive compensation, Twist Bioscience, Patrick John Finn, vesting